Literature DB >> 23922144

Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intervention: analysis from the national cardiovascular data registry.

Dmitri V Baklanov1, Sunghee Kim, Steven P Marso, Sumeet Subherwal, Sunil V Rao.   

Abstract

BACKGROUND: Bleeding is a common, noncardiac, preventable complication of percutaneous coronary intervention. We compared the relative safety of radial access and bivalirudin in percutaneous coronary intervention. METHODS AND
RESULTS: From CathPCI Registry, we determined the association between the site of arterial access, bivalirudin, and periprocedural bleeding rates in 501 017 patients. Radial access patients receiving heparin (radial group) were compared with those receiving bivalirudin (radial combination group). Femoral access patients who had bivalirudin and a vascular closure device served as a reference group (femoral group). An inverse probability weighting analysis incorporating propensity scores was used to compare groups. The overall rate of bleeding was 2.59%. It was 2.71% in the femoral group, 2.5% in the radial group, and 1.82% in the radial combination groups (P<0.001). When compared with femoral group, the adjusted odds ratio for bleeding was significantly lower for patients with radial combination group (odds ratio, 0.79; 95% confidence interval, 0.72-0.86), but not for radial group (odds ratio, 0.96; 95% confidence interval, 0.88-1.05), unless patients treated with IIb/IIIa were excluded (radial group-IIb/IIIa odds ratio, 0.84; 95% confidence interval, 0.75-0.94).The number needed to treat to prevent 1 bleeding event with radial combination group was 138, whereas the number needed to treat to prevent 1 bleeding event in high-bleeding risk patients was 68.
CONCLUSIONS: In this observational analysis, the combination of bivalirudin and radial access was associated with reduced bleeding event rate. This benefit was present across the entire spectrum of preprocedural risk of bleeding, with or without exposure to IIb/IIIa inhibitors. These data support an adequately powered randomized trial comparing bleeding avoidance strategies.

Entities:  

Keywords:  bivalirudin; hemorrhage; percutaneous coronary intervention; radial access

Mesh:

Substances:

Year:  2013        PMID: 23922144      PMCID: PMC3936790          DOI: 10.1161/CIRCINTERVENTIONS.113.000279

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  24 in total

1.  The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR): building a national clinical data repository.

Authors:  R G Brindis; S Fitzgerald; H V Anderson; R E Shaw; W S Weintraub; J F Williams
Journal:  J Am Coll Cardiol       Date:  2001-06-15       Impact factor: 24.094

2.  Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center.

Authors:  Olivier Barthélémy; Johanne Silvain; David Brieger; Anne Mercadier; Remi Lancar; Anne Bellemain-Appaix; Farzin Beygui; Jean Philippe Collet; Dominique Costagliola; Gilles Montalescot
Journal:  Catheter Cardiovasc Interv       Date:  2011-12-08       Impact factor: 2.692

3.  Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.

Authors:  Adnan Kastrati; Franz-Josef Neumann; Julinda Mehilli; Robert A Byrne; Raisuke Iijima; Heinz Joachim Büttner; Ahmed A Khattab; Stefanie Schulz; James C Blankenship; Jürgen Pache; Jan Minners; Melchior Seyfarth; Isolde Graf; Kimberly A Skelding; Josef Dirschinger; Gert Richardt; Peter B Berger; Albert Schömig
Journal:  N Engl J Med       Date:  2008-08-14       Impact factor: 91.245

4.  The American College of Cardiology National Database: progress and challenges. American College of Cardiology Database Committee.

Authors:  W S Weintraub; C R McKay; R N Riner; S G Ellis; P L Frommer; D B Carmichael; K E Hammermeister; M N Effros; J E Bost; D P Bodycombe
Journal:  J Am Coll Cardiol       Date:  1997-02       Impact factor: 24.094

5.  Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention.

Authors:  Gjin Ndrepepa; Tibor Schuster; Martin Hadamitzky; Robert A Byrne; Julinda Mehilli; Franz-Josef Neumann; Gert Richardt; Stefanie Schulz; Karl-Ludwig Laugwitz; Steffen Massberg; Albert Schömig; Adnan Kastrati
Journal:  Circulation       Date:  2012-02-17       Impact factor: 29.690

6.  Impact of transradial and transfemoral coronary interventions on bleeding and net adverse clinical events in acute coronary syndromes.

Authors:  Martial Hamon; Shamir Mehta; Ph Gabriel Steg; David Faxon; Prafulla Kerkar; Hans-Jürgen Rupprecht; Jean-François Tanguay; Rizwan Afzal; Salim Yusuf
Journal:  EuroIntervention       Date:  2011-05       Impact factor: 6.534

7.  Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.

Authors:  John W Eikelboom; Shamir R Mehta; Sonia S Anand; Changchun Xie; Keith A A Fox; Salim Yusuf
Journal:  Circulation       Date:  2006-08-14       Impact factor: 29.690

8.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

Authors:  A Michael Lincoff; John A Bittl; Robert A Harrington; Frederick Feit; Neal S Kleiman; J Daniel Jackman; Ian J Sarembock; David J Cohen; Douglas Spriggs; Ramin Ebrahimi; Gadi Keren; Jeffrey Carr; Eric A Cohen; Amadeo Betriu; Walter Desmet; Dean J Kereiakes; Wolfgang Rutsch; Robert G Wilcox; Pim J de Feyter; Alec Vahanian; Eric J Topol
Journal:  JAMA       Date:  2003-02-19       Impact factor: 56.272

9.  Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry.

Authors:  Sripal Bangalore; David J Cohen; Neal S Kleiman; Tal Regev-Beinart; Sunil V Rao; Michael J Pencina; Laura Mauri
Journal:  Circ Cardiovasc Interv       Date:  2011-10-04       Impact factor: 6.546

10.  Bivalirudin during primary PCI in acute myocardial infarction.

Authors:  Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Ajay J Kirtane; Helen Parise; Roxana Mehran
Journal:  N Engl J Med       Date:  2008-05-22       Impact factor: 91.245

View more
  9 in total

1.  The comparative efficacy of bivalirudin is markedly attenuated by use of radial access: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium.

Authors:  Emily Perdoncin; Milan Seth; Simon Dixon; Louis Cannon; Akshay Khandelwal; Arthur Riba; Shukri David; David Wohns; Hitinder Gurm
Journal:  Eur Heart J       Date:  2015-09-15       Impact factor: 29.983

2.  Influence of Access, Anticoagulant, and Bleeding Definition on Outcomes of Primary Percutaneous Coronary Intervention: Early Experience of an US Academic Center.

Authors:  M K Bheemarasetti; S Shawar; S Chithri; W I Khalife; U M Rangasetty; K Fujise; S A Gilani
Journal:  Int J Angiol       Date:  2015-03

3.  Access site complications after peripheral vascular interventions: incidence, predictors, and outcomes.

Authors:  Daniel Ortiz; Arshad Jahangir; Maharaj Singh; Suhail Allaqaband; Tanvir K Bajwa; Mark W Mewissen
Journal:  Circ Cardiovasc Interv       Date:  2014-11-11       Impact factor: 6.546

Review 4.  Same day discharge after elective percutaneous coronary intervention.

Authors:  Ian C Gilchrist
Journal:  Curr Cardiol Rep       Date:  2014-04       Impact factor: 2.931

5.  Change in hospital-level use of transradial percutaneous coronary intervention and periprocedural outcomes: insights from the national cardiovascular data registry.

Authors:  Steven M Bradley; Sunil V Rao; Jeptha P Curtis; Craig S Parzynski; John C Messenger; Stacie L Daugherty; John S Rumsfeld; Hitinder S Gurm
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-06-04

6.  Development and Evaluation of Novel Electronic Medical Record Tools For Avoiding Bleeding After Percutaneous Coronary Intervention.

Authors:  Joseph Ebinger; Timothy Henry; Sungjin Kim; Moira Inkelas; Susan Cheng; Teryl Nuckols
Journal:  J Am Heart Assoc       Date:  2019-11-11       Impact factor: 5.501

7.  Simplified swift and safe vascular closure device deployment without a local arteriogram: Single center experience in 2074 consecutive patients.

Authors:  Antonis S Manolis; Georgios Georgiopoulos; Dimitris Stalikas; Spyridon Koulouris
Journal:  Indian Heart J       Date:  2016-01-11

8.  Reversing the "Risk-Treatment Paradox" of Bleeding in Patients Undergoing Percutaneous Coronary Intervention: Risk-Concordant Use of Bleeding Avoidance Strategies Is Associated With Reduced Bleeding and Lower Costs.

Authors:  Amit P Amin; Samantha Miller; Brandon Rahn; Mary Caruso; Andrew Pierce; Katrine Sorensen; Howard Kurz; Alan Zajarias; Richard Bach; Jasvindar Singh; John M Lasala; Hemant Kulkarni; Patricia Crimmins-Reda
Journal:  J Am Heart Assoc       Date:  2018-11-06       Impact factor: 5.501

9.  Associations Between Hospital Length of Stay, 30-Day Readmission, and Costs in ST-Segment-Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention: A Nationwide Readmissions Database Analysis.

Authors:  Sun-Joo Jang; Ilhwan Yeo; Dmitriy N Feldman; Jim W Cheung; Robert M Minutello; Harsimran S Singh; Geoffrey Bergman; S Chiu Wong; Luke K Kim
Journal:  J Am Heart Assoc       Date:  2020-05-29       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.